Resource, News and Events
Bantam Pharmaceutical Announces First Patient Treated in BTM-3566
Phase 1 Clinical Trial at Princess Margaret Cancer Centre in Toronto
December 10, 2025
TPS7097: A Phase 1 Trial of BTM-3566 in Relapsed/Refractory
Mature B Cell Lymphomas
June 1, 2025
Bantam Pharmaceutical to Present at the American Society of Clinical Oncology (ASCO) 2025
Annual Meeting
May 22, 2025
Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces
regression in tumors expressing low levels of FAM210B
April 28, 2025
Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American
Association for Cancer Research (AACR) Annual Meeting 2025
April 25, 2025
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
February 20, 2025
Bantam Pharmaceutical to Present at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025
Bantam Pharmaceutical Accelerates BTM-3566 Clinical Program Expanding Phase 1 Trial into
Canada
March 6, 2025
Solid Tumor Data Presented at 36th EORTC Symposium on Molecular Targets & Cancer Therapeutics
December 18, 2024
Bantam Data in Collaboration with MD Anderson Presented at 2024 AACR Conference
July 30, 2024
Bantam & Collaborators Published in Molecular Cancer Therapeutics, an AACR Journal
September 6, 2023
Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 Abstract DLBCL are aggressive, rapidly proliferating tumors that critically depend on the ATF4-mediated integrated stress response (ISR) to adapt to stress caused by uncontrolled growth, such as hypoxia, amino acid deprivation and accumulation of misfolded proteins. Here we show that ISR hyperactivation is […]
BANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023
January 9, 2023
Developing Novel Selective Modulators of Mitochondrial Dynamics (SeMMiDs)A differentiated therapeutic approach for treating aggressive cancer Raleigh, NC. January 9th, 2023 – Bantam Pharmaceutical, LLC announces that it is presenting at the Biotech Showcase taking place in San Francisco, the 9th-11th of January and virtually, on demand the 18th and 19th of January. Bantam Pharmaceutical is […]
Bantam Pharma Featured in Nature BioPharma Dealmakers
September 1, 2023
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting – Advances in Malignant Lymphoma
June 23, 2022
RESEARCH TRIANGLE PARK, N.C., June 23, 2022 /PRNewswire/ — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that new data on the mechanism of action of its lead clinical candidate BTM-3566 will be presented at the Third AACR International Meeting – Advances in Malignant Lymphoma taking place on the 23-26 […]
Data on Bantam Pharmaceutical’s Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual ASH Meeting
December 13, 2021
BTM-3566 demonstrated robust therapeutic responses in Diffuse Large B-Cell Lymphoma models, both in vitro and in vivo RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2021 /PRNewswire/ — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that data on the activity and mechanism of BTM-3566, a novel, first-in-class oral compound […]
Bantam Pharma Featured in Nature BioPharma Dealmakers
April 8, 2022
RESEARCH TRIANGLE PARK, N.C., April 8th, 2022 – Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans. The data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control […]
Bantam Patent Coverage through 2039
November 24, 2021
First Patents Published December, 2016 WO2016196644A1 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto WO2018102453 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases WO2018102452 Methods of using substituted pyrazole and pyrazole compounds and for […]
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology
November 18, 2021
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology Oral Presentation Will Focus on InVitro and InVivo Responses to BTM-3566 in Diffuse Large B-Cell Lymphoma RESEARCH TRIANGLE PARK, N.C., November 18, 2021 — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics […]
Bantam Pharmaceutical Completes $25 Million Seed Funding
September 16, 2021
Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park NEWS PROVIDED BY Bantam Pharmaceutical, LLC Sep 16, 2021, 08:00 ET Bantam plans to submit its Investigational New […]
Bantam Pharmaceutical Appoints Industry Veteran
April 27, 2021
Bantam Pharmaceutical Appoints Industry Veteran Michael Stocum as President and Chief Executive Officer New York, N.Y. – April 27, 2021 —Bantam Pharmaceutical, a drug discovery, and development company targeting selective modulation of mitochondrial dynamics in cancer, announced today that it has named Michael Stocum, MS as President and Chief Executive Officer. Mr. Stocum succeeds the […]
Bantam Presents at the AACR Virtual Meeting: Advances in Malignant Lymphoma – August 2020
August 2, 2020
Bantam Presents at the Inaugural AACR Advances in Malignant Lymphoma Meeting – June 2018
July 6, 2018
Bantam Publication in Bioorganic & Medicinal Chemistry Letters – June 2017
July 6, 2017